69,645 Shares in Albemarle Corporation $ALB Bought by BNP Paribas

BNP Paribas bought a new stake in Albemarle Corporation (NYSE:ALB – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 69,645 shares of the specialty chemicals company’s stock, valued at approximately $7,367,000. BNP Paribas owned about 0.06% of Albemarle at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ALB. Allspring Global Investments Holdings LLC lifted its stake in Albemarle by 0.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 11,664 shares of the specialty chemicals company’s stock worth $2,082,000 after purchasing an additional 75 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in Albemarle by 7.0% in the second quarter. Parkside Financial Bank & Trust now owns 1,584 shares of the specialty chemicals company’s stock valued at $214,000 after purchasing an additional 103 shares during the period. Parallel Advisors LLC raised its position in Albemarle by 4.9% in the 1st quarter. Parallel Advisors LLC now owns 2,588 shares of the specialty chemicals company’s stock valued at $465,000 after purchasing an additional 120 shares in the last quarter. Empirical Finance LLC increased its position in shares of Albemarle by 3.4% in the 2nd quarter. Empirical Finance LLC now owns 4,272 shares of the specialty chemicals company’s stock valued at $577,000 after purchasing an additional 141 shares during the last quarter. Finally, Tema ETFs LLC boosted its position in shares of Albemarle by 6.9% during the 2nd quarter. Tema ETFs LLC now owns 2,249 shares of the specialty chemicals company’s stock worth $304,000 after acquiring an additional 145 shares in the last quarter. Institutional investors and hedge funds own 92.87% of the company’s stock.

Albemarle Trading Down 4.1%

Shares of Albemarle stock opened at $79.54 on Friday. Albemarle Corporation has a 1 year low of $79.38 and a 1 year high of $221.00. The company has a market capitalization of $9.39 billion, a P/E ratio of 19.21, a P/E/G ratio of 0.50 and a beta of 1.34. The business has a 50 day moving average price of $99.63 and a 200 day moving average price of $143.32. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.34 and a quick ratio of 1.57.

Albemarle (NYSE:ALB – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The specialty chemicals company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. Albemarle had a net margin of 10.40% and a return on equity of 14.91%. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.52 billion. During the same period in the prior year, the firm posted ($0.19) EPS. The company’s revenue was up 18.8% on a year-over-year basis. Sell-side analysts anticipate that Albemarle Corporation will post 10.64 EPS for the current fiscal year.

Albemarle Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Friday, December 18th will be given a $0.41 dividend. The ex-dividend date is Friday, December 18th. This represents a $1.64 annualized dividend and a dividend yield of 2.1%. Albemarle’s dividend payout ratio (DPR) is presently 39.61%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Barclays dropped their price objective on Albemarle from $109.00 to $95.00 and set an “equal weight” rating on the stock in a report on Friday, November 6th. Rothschild & Co Redburn cut their price target on Albemarle from $100.00 to $86.00 in a research report on Wednesday, November 11th. Argus reduced their price objective on Albemarle from $230.00 to $135.00 and set a “buy” rating for the company in a research note on Wednesday, October 7th. Robert W. Baird reduced their price target on shares of Albemarle from $157.00 to $123.00 in a research report on Wednesday, October 14th. Finally, BMO Capital Markets lowered their price objective on shares of Albemarle from $200.00 to $175.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 6th. Fifteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Albemarle has a consensus rating of “Moderate Buy” and an average price target of $152.63.

Get Our Latest Stock Report on ALB

Albemarle Company Profile

(Free Report)

Albemarle Corporation is a specialty chemicals company that produces lithium, bromine and refining catalysts. Its products serve industries including energy storage, transportation, electronics, petroleum refining and pharmaceuticals. The company supplies lithium compounds used in rechargeable batteries and other applications. It also makes bromine-based products for uses such as flame retardants and water treatment, along with catalysts used in refining petroleum. Albemarle traces its history to 1887 and is headquartered in Charlotte, North Carolina.

Recommended Stories

Institutional Ownership by Quarter for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.